CURVEBEAM AI LIMITED (CVB)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

CVB - CURVEBEAM AI LIMITED

FNArena Sector : Medical Equipment & Devices
Year End: June
GICS Industry Group : NONE
Debt/EBITDA: -4.27
Index:

LAST PRICE CHANGE +/- CHANGE % VOLUME

$0.125

20 Dec
2024

0.010

OPEN

$0.12

8.70%

HIGH

$0.13

235,921

LOW

$0.13

TARGET
$0.26 108.0% upside
OTHER COMPANIES IN THE SAME SECTOR
4DX . AT1 . AYA . BB1 . BRN . CAT . CBL . CGS . CMP . COH . CSX . CU6 . CYC . EBR . EMV . EYE . FPH . IDX . IME . IMR . IPD . LDX . MX1 . NAN . ONE . PCK . PEB . PGC . PME . RMD . SOM . TRJ . UBI . VTI .
FNARENA'S MARKET CONSENSUS FORECASTS
CVB: 1
Title FY22
Actual		 FY23
Actual		 FY24
Forecast		 FY25
Forecast
EPS (cps) xxx - 15.5 - 6.7 xxx
DPS (cps) xxx 0.0 0.0 xxx
EPS Growth xxx N/A N/A xxx
DPS Growth xxx N/A N/A xxx
PE Ratio xxx N/A N/A xxx
Dividend Yield xxx N/A 0.0% xxx
Div Pay Ratio(%) xxx N/A N/A xxx

Dividend yield today if purchased 3 years ago: N/A

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 N/A

Estimated Dividend Growth
(Average Of Past Three Years)

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages
HISTORICAL DATA ARE ALL IN AUD
Copyright © 2024 FactSet UK Limited. All rights reserved
Title 20232024
EPS Basic xxx-7.9
DPS All xxx0.0
Sales/Revenue xxx6.5 M
Book Value Per Share xxx11.8
Net Operating Cash Flow xxx-21.9 M
Net Profit Margin xxx-353.94 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 20232024
Return on Capital Employed xxx-
Return on Invested Capital xxx-60.78 %
Return on Assets xxx-37.05 %
Return on Equity xxx-
Return on Total Capital xxx-60.80 %
Free Cash Flow ex dividends xxx-21.9 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 20232024
Short-Term Debt xxx1 M
Long Term Debt xxx15 M
Total Debt xxx16 M
Goodwill - Gross xxx20 M
Cash & Equivalents - Generic xxx6 M
Price To Book Value xxx1.31

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 20232024
Capex xxx0.3 M
Capex % of Sales xxx4.96 %
Cost of Goods Sold xxx22 M
Selling, General & Admin. Exp & Other xxx9 M
Research & Development xxx1 M
Investments - Total xxx0 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

1.0

No. Of Recommendations

1
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Bell Potter

05/09/2024

1

Speculative Buy

$0.26

108.00%

The 10 purchase orders for new devices in the 4Q of FY24 are yet to be delivered and installed, resulting in a material miss for Curvebeam AI's FY24 revenue against Bell Potter's forecast.

Sales of the HiRise (foot and ankle) in FY24 were well below management's expectation, but validation of the Enhanced HiRise (aka HiRise 2.0) for the more lucrative hip and knee surgeries will drive sales, suggest the analysts.

In early-FY25, management placed shares of $11.58m taking the effective cash balance to $18.1m. The company is now funded for FY25 and possibly well beyond, suggests the broker.

The Speculative Buy rating is unchanged, and the broker's target decreased to 26c from 35c.

FORECAST
Bell Potter forecasts a full year FY24 dividend of 0.00 cents and EPS of minus -6.70 cents.
Bell Potter forecasts a full year FY25 dividend of 0.00 cents and EPS of minus -4.80 cents.
Access Stockbroker Research History >
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

0

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY
Access Extra Coverage Research History >

CVB STOCK CHART

FNArena News on CVB

1
FNArena Corporate Results Monitor – 06-09-2024

Sep 06 2024 - Australia

Latest Medical Equipment & Devices News

1
Diagnostic Imaging Radiates Opportunity

Dec 18 2024 - Small Caps
2
ResMed’s Bounce-Back Complete

Oct 29 2024 - Australia
3
Dr Boreham’s Crucible: Pro Medicus

Sep 04 2024 - Australia
4
Pro Medicus: Don’t Stop Me Now

Aug 20 2024 - Technicals
5
Dr Boreham’s Crucible: Blinklab

May 20 2024 - Small Caps
6
ResMed Silences The Doubters

Apr 29 2024 - Australia
7
Dr Boreham’s Crucible: 4D Medical

Apr 23 2024 - Small Caps
8
Uptrend Resumed For ResMed

Mar 19 2024 - Technicals
9
Dr Boreham’s Crucible: Cochlear

Feb 28 2024 - Australia
10
Rudi Interviewed: Ongoing Potential In Technology & Growth

Feb 19 2024 - Rudi's View